<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Dermatomyositis - By Meshal Bukhari</title>
    <style>
        /* Force all font weights to black (900) */
        * {
            font-weight: 900 !important;
        }
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            color: #333;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
            background: white;
            box-shadow: 0 0 30px rgba(0,0,0,0.1);
            border-radius: 15px;
            margin-top: 20px;
            margin-bottom: 20px;
        }

        .header {
            text-align: center;
            background: linear-gradient(135deg, #667eea, #764ba2);
            color: white;
            padding: 30px;
            border-radius: 15px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .header::before {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            right: 0;
            bottom: 0;
            background: url('data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100"><defs><pattern id="grain" width="100" height="100" patternUnits="userSpaceOnUse"><circle cx="25" cy="25" r="1" fill="rgba(255,255,255,0.1)"/><circle cx="75" cy="75" r="0.5" fill="rgba(255,255,255,0.1)"/><circle cx="50" cy="10" r="0.8" fill="rgba(255,255,255,0.1)"/></pattern></defs><rect width="100" height="100" fill="url(%23grain)"/></svg>');
            opacity: 0.3;
        }

        .header h1 {
            font-size: 2.5em;
            margin-bottom: 10px;
            position: relative;
            z-index: 1;
        }

        .header .subtitle {
            font-size: 1.2em;
            opacity: 0.9;
            position: relative;
            z-index: 1;
        }

        .nav-tabs {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-bottom: 30px;
            border-bottom: 3px solid #667eea;
            padding-bottom: 15px;
        }

        .nav-tab {
            background: linear-gradient(135deg, #667eea, #764ba2);
            color: white;
            border: none;
            padding: 12px 20px;
            border-radius: 25px;
            cursor: pointer;
            transition: all 0.3s ease;
            
            font-size: 14px;
        }

        .nav-tab:hover, .nav-tab.active {
            transform: translateY(-2px);
            box-shadow: 0 5px 15px rgba(102, 126, 234, 0.4);
            background: linear-gradient(135deg, #764ba2, #667eea);
        }

        .section {
            display: none;
            animation: fadeIn 0.5s ease-in;
        }

        .section.active {
            display: block;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(20px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .high-yield {
            background: linear-gradient(135deg, #ff6b6b, #ee5a24);
            color: white;
            padding: 20px;
            border-radius: 12px;
            margin: 20px 0;
            border-left: 5px solid #ff3838;
            position: relative;
            overflow: hidden;
        }

        .high-yield::before {
            content: 'üî• HIGH YIELD';
            position: absolute;
            top: 10px;
            right: 15px;
            font-size: 12px;
            
            opacity: 0.8;
        }

        .clinical-pearl {
            background: linear-gradient(135deg, #f093fb, #f5576c);
            color: white;
            padding: 15px;
            border-radius: 10px;
            margin: 15px 0;
            border-left: 4px solid #e056fd;
        }

        .clinical-pearl::before {
            content: 'üíé PEARL: ';
            
        }

        .mcq-focus {
            background: linear-gradient(135deg, #4facfe, #00f2fe);
            color: white;
            padding: 15px;
            border-radius: 10px;
            margin: 15px 0;
            border-left: 4px solid #0984e3;
        }

        .mcq-focus::before {
            content: 'üéØ MCQ FOCUS: ';
            
        }

        .antibody-card {
            background: white;
            border: 2px solid #ddd;
            border-radius: 12px;
            padding: 20px;
            margin: 15px 0;
            transition: all 0.3s ease;
            cursor: pointer;
            position: relative;
        }

        .antibody-card:hover {
            border-color: #667eea;
            transform: translateY(-3px);
            box-shadow: 0 8px 25px rgba(102, 126, 234, 0.15);
        }

        .antibody-name {
            font-size: 1.4em;
            
            color: #667eea;
            margin-bottom: 10px;
        }

        .prevalence {
            background: #667eea;
            color: white;
            padding: 5px 12px;
            border-radius: 20px;
            display: inline-block;
            font-size: 12px;
            
            position: absolute;
            top: 15px;
            right: 15px;
        }

        .feature-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }

        .feature-card {
            background: #f8f9ff;
            border: 1px solid #e1e5ff;
            border-radius: 10px;
            padding: 20px;
            transition: all 0.3s ease;
        }

        .feature-card:hover {
            border-color: #667eea;
            background: #f0f3ff;
        }

        .pathognomonic {
            border-left: 5px solid #e74c3c;
            background: #fdf2f2;
        }

        .characteristic {
            border-left: 5px solid #f39c12;
            background: #fef9f3;
        }

        .compatible {
            border-left: 5px solid #27ae60;
            background: #f2f8f5;
        }

        .rare {
            border-left: 5px solid #8e44ad;
            background: #f8f4f9;
        }

        .system-involvement {
            background: linear-gradient(135deg, #a8edea, #fed6e3);
            padding: 20px;
            border-radius: 12px;
            margin: 20px 0;
        }

        .treatment-box {
            background: linear-gradient(135deg, #d299c2, #fef9d7);
            border: 2px solid #d63384;
            border-radius: 12px;
            padding: 20px;
            margin: 20px 0;
        }

        .prognosis-good {
            background: linear-gradient(135deg, #52c234, #38ef7d);
            color: white;
            padding: 15px;
            border-radius: 10px;
            margin: 10px 0;
        }

        .prognosis-poor {
            background: linear-gradient(135deg, #ff4757, #ff3742);
            color: white;
            padding: 15px;
            border-radius: 10px;
            margin: 10px 0;
        }

        .flip-card {
            background-color: transparent;
            width: 100%;
            height: 200px;
            perspective: 1000px;
            margin: 15px 0;
        }

        .flip-card-inner {
            position: relative;
            width: 100%;
            height: 100%;
            text-align: center;
            transition: transform 0.6s;
            transform-style: preserve-3d;
            cursor: pointer;
        }

        .flip-card:hover .flip-card-inner {
            transform: rotateY(180deg);
        }

        .flip-card-front, .flip-card-back {
            position: absolute;
            width: 100%;
            height: 100%;
            backface-visibility: hidden;
            border-radius: 12px;
            display: flex;
            align-items: center;
            justify-content: center;
            padding: 20px;
            
        }

        .flip-card-front {
            background: linear-gradient(135deg, #667eea, #764ba2);
            color: white;
        }

        .flip-card-back {
            background: linear-gradient(135deg, #f093fb, #f5576c);
            color: white;
            transform: rotateY(180deg);
        }

        .memory-tip {
            background: #fff3cd;
            border: 1px solid #ffeaa7;
            border-radius: 8px;
            padding: 15px;
            margin: 15px 0;
            border-left: 4px solid #fdcb6e;
        }

        .memory-tip::before {
            content: 'üß† MEMORY TIP: ';
            
            color: #e17055;
        }

        .quick-facts {
            background: linear-gradient(135deg, #74b9ff, #0984e3);
            color: white;
            padding: 20px;
            border-radius: 12px;
            margin: 20px 0;
        }

        .fact-item {
            display: flex;
            align-items: center;
            margin: 10px 0;
            
        }

        .fact-item::before {
            content: '‚úì';
            background: rgba(255,255,255,0.2);
            border-radius: 50%;
            width: 25px;
            height: 25px;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 15px;
            
        }

        .interactive-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background: white;
            border-radius: 12px;
            overflow: hidden;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }

        .interactive-table th {
            background: linear-gradient(135deg, #667eea, #764ba2);
            color: white;
            padding: 15px;
            text-align: left;
            
        }

        .interactive-table td {
            padding: 12px 15px;
            border-bottom: 1px solid #eee;
            transition: background 0.3s ease;
        }

        .interactive-table tr:hover td {
            background: #f8f9ff;
        }

        .malignancy-alert {
            background: linear-gradient(135deg, #ff6b6b, #ee5a24);
            color: white;
            padding: 20px;
            border-radius: 12px;
            margin: 20px 0;
            border: 3px solid #ff3838;
            position: relative;
        }

        .malignancy-alert::before {
            content: '‚ö†Ô∏è MALIGNANCY RISK';
            position: absolute;
            top: -12px;
            left: 20px;
            background: #ff3838;
            padding: 5px 15px;
            border-radius: 15px;
            font-size: 12px;
            
        }

        @media (max-width: 768px) {
            .nav-tabs {
                flex-direction: column;
            }
            
            .feature-grid {
                grid-template-columns: 1fr;
            }
            
            .container {
                margin: 10px;
                padding: 15px;
            }
            
            .header h1 {
                font-size: 2em;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>DERMATOMYOSITIS</h1>
            <div class="subtitle">Saudi Board Exam - Final Year Preparation</div>
        </div>

        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showSection('overview')">Overview & Antibodies</button>
            <button class="nav-tab" onclick="showSection('epidemiology')">Epidemiology & Pathogenesis</button>
            <button class="nav-tab" onclick="showSection('classification')">Classification</button>
            <button class="nav-tab" onclick="showSection('clinical')">Clinical Features</button>
            <button class="nav-tab" onclick="showSection('systemic')">Systemic Involvement</button>
            <button class="nav-tab" onclick="showSection('malignancy')">Malignancy</button>
            <button class="nav-tab" onclick="showSection('diagnosis')">Diagnosis & DDx</button>
            <button class="nav-tab" onclick="showSection('treatment')">Treatment & Prognosis</button>
            <button class="nav-tab" onclick="showSection('oral-exam')">Oral Exam Questions</button>
            
        </div>

        <!-- OVERVIEW & ANTIBODIES SECTION -->
        <div id="overview" class="section active">
            <h2>üéØ Dermatomyositis Overview & Antibody Targets</h2>
            
            <div class="high-yield">
                <h3>üî• HIGH YIELD: Key Antibody-Clinical Associations</h3>
                <p>Master these antibody patterns - they're heavily tested and clinically crucial for prognosis and treatment decisions!</p>
            </div>

            <div class="feature-grid">
                <div class="antibody-card">
                    <div class="prevalence">80% Amyopathic</div>
                    <div class="antibody-name">P155 (TIF-1Œ≥)</div>
                    <p><strong>Target:</strong> Transcriptional intermediary factor 1 gamma</p>
                    <div class="clinical-pearl">
                        <strong>Clinical Associations:</strong>
                        <ul>
                            <li>80% clinically amyopathic DM</li>
                            <li>20-30% classic DM</li>
                            <li>‚ö†Ô∏è Increased malignancy risk</li>
                            <li>Extensive cutaneous involvement</li>
                            <li>Palatal erythema ("ovoid patches")</li>
                            <li>Psoriasiform lesions</li>
                            <li>Palmar hyperkeratotic papules</li>
                            <li>"Red on white" patches (hypopigmented + telangiectatic)</li>
                        </ul>
                    </div>
                </div>

                <div class="antibody-card">
                    <div class="prevalence">15%</div>
                    <div class="antibody-name">Mi-2 (Most Specific)</div>
                    <p><strong>Target:</strong> Helicase nuclear proteins</p>
                    <div class="mcq-focus">
                        <strong>MCQ FOCUS:</strong> Most specific antibody for DM!
                    </div>
                    <div class="clinical-pearl">
                        <strong>Clinical Associations:</strong>
                        <ul>
                            <li>‚úÖ Milder muscle disease</li>
                            <li>‚úÖ Good response to treatment</li>
                            <li>Classic triad: Gottron papules/sign, Shawl sign, Cuticular changes</li>
                        </ul>
                    </div>
                </div>

                <div class="antibody-card">
                    <div class="prevalence">JO-1: 20%</div>
                    <div class="antibody-name">Antisynthetase (JO-1, PL7, PL12)</div>
                    <p><strong>Target:</strong> tRNA synthetase</p>
                    <div class="clinical-pearl">
                        <strong>Antisynthetase Syndrome:</strong>
                        <ul>
                            <li>üå°Ô∏è Fever</li>
                            <li>ü´Å Interstitial lung disease (ILD)</li>
                            <li>ü¶¥ Arthritis</li>
                            <li>üßä Raynaud's phenomenon</li>
                            <li>üëê Mechanic's hands</li>
                        </ul>
                    </div>
                    <div class="memory-tip">
                        Remember "FARM" - Fever, Arthritis, Raynaud's, Mechanic's hands + ILD
                    </div>
                </div>

                <div class="antibody-card">
                    <div class="prevalence">5%</div>
                    <div class="antibody-name">SRP</div>
                    <p><strong>Target:</strong> Signal recognition particle</p>
                    <div class="clinical-pearl">
                        <strong>Clinical Associations:</strong>
                        <ul>
                            <li>‚ö° Fulminant DM/PM</li>
                            <li>‚ù§Ô∏è Cardiac involvement</li>
                            <li>üí™ Severe weakness, high CK</li>
                            <li>üõ°Ô∏è May be refractory to treatment</li>
                        </ul>
                    </div>
                </div>

                <div class="antibody-card">
                    <div class="prevalence">10-40%</div>
                    <div class="antibody-name">MDA5/CADM-140</div>
                    <p><strong>Target:</strong> Melanoma differentiation-associated protein 5</p>
                    <div class="high-yield">
                        <strong>High-Yield Clinical Pattern:</strong>
                        <ul>
                            <li>Clinically amyopathic DM</li>
                            <li>ü´Å Rapidly progressive ILD (POOR PROGNOSIS)</li>
                            <li>Cutaneous ulcerations with vasculopathy</li>
                            <li>Tender palmar papules</li>
                            <li>Oral pain and ulceration</li>
                            <li>Non-scarring alopecia</li>
                            <li>High aldolase</li>
                            <li>Panniculitis</li>
                        </ul>
                    </div>
                </div>

                <div class="antibody-card">
                    <div class="prevalence">Adults: 1-15%</div>
                    <div class="antibody-name">NXP2</div>
                    <p><strong>Target:</strong> Nuclear matrix protein NXP2</p>
                    <div class="clinical-pearl">
                        <strong>Age-Dependent Associations:</strong>
                        <ul>
                            <li><strong>Adults:</strong> Malignancy, subcutaneous edema, calcinosis, severe dysphagia</li>
                            <li><strong>Juveniles (20-25%):</strong> Severe muscle disease + calcinosis</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="quick-facts">
                <h3>üîç ANA Patterns - Quick Facts</h3>
                <div class="fact-item">45-60% of DM patients are ANA positive</div>
                <div class="fact-item">Adult-onset amyopathic DM: 65% ANA positive</div>
                <div class="fact-item">Pattern: Speckled, nucleolar</div>
                <div class="fact-item">Antisynthetase syndrome: ANA NEGATIVE</div>
            </div>
        </div>

        <!-- EPIDEMIOLOGY & PATHOGENESIS SECTION -->
        <div id="epidemiology" class="section">
            <h2>üìä Epidemiology & Pathogenesis</h2>

            <div class="quick-facts">
                <h3>üìà Epidemiology Essentials</h3>
                <div class="fact-item">Female predominance: F:M = 2-3:1 (all types)</div>
                <div class="fact-item">Bimodal age distribution</div>
                <div class="fact-item">Juvenile peak: 5-14 years</div>
                <div class="fact-item">Adult peak: 45-65 years</div>
            </div>

            <div class="flip-card">
                <div class="flip-card-inner">
                    <div class="flip-card-front">
                        <h3>üß¨ HLA Associations<br>(Hover to reveal)</h3>
                    </div>
                    <div class="flip-card-back">
                        <div style="font-size: 14px;">
                            <strong>Juvenile DM:</strong> HLA-DR3, -B8<br>
                            <strong>Anti-Jo-1:</strong> HLA-DR52<br>
                            <strong>Anti-Mi-2:</strong> HLA-DR7, -DRw53<br>
                            <strong>Adult DM overlap:</strong> HLA-B14, -B40
                        </div>
                    </div>
                </div>
            </div>

            <div class="mcq-focus">
                <strong>MCQ Focus:</strong> TNF-Œ± 308A allele polymorphism - commonly tested genetic association
            </div>

            <div class="system-involvement">
                <h3>ü¶† Infectious Triggers</h3>
                <table class="interactive-table">
                    <thead>
                        <tr>
                            <th>Pathogen</th>
                            <th>Association</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>E. coli</td>
                            <td>Anti-JO-1 antibodies</td>
                        </tr>
                        <tr>
                            <td>Coxsackievirus</td>
                            <td>Echovirus in hypogammaglobulinemia</td>
                        </tr>
                        <tr>
                            <td>HIV, HTLV-1</td>
                            <td>Viral trigger</td>
                        </tr>
                        <tr>
                            <td>Parvovirus B19</td>
                            <td>Viral trigger</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="high-yield">
                <h3>üíä Drug-Induced Dermatomyositis</h3>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4 style="color: black;">Hydroxyurea</h4>
                        <p style="color: black;"><strong>Presentation:</strong> Cutaneous DM features + painful leg ulcers, xerosis, skin atrophy</p>
                        <p style="color: black;"><strong>Timeline:</strong> 2-10 years of treatment</p>
                    </div>
                    <div class="feature-card">
                        <h4 style="color: black;">Statins</h4>
                        <p style="color: black;"><strong>Presentation:</strong> Cutaneous DM + muscle symptoms</p>
                        <p style="color: black;"><strong>Timeline:</strong> Average 2 months</p>
                    </div>

                    <div class="feature-card">
                        <h4 style="color: black;">Others</h4>
                        <p style="color: black;">Gemfibrozil, TNF-Œ± inhibitors, NSAID, cyclophosphamide, checkpoint inhibitors, BCG vaccine, D-penicillamine, phenytoin</p>
                    </div>
                </div>
                <div class="clinical-pearl">
                    <p style="color: black;">Most common drug-induced features: Heliotrope rash + Gottron papules. Resolution in 2 months after discontinuation.</p>
                </div>
            </div>

            <div class="mcq-focus">
                <strong style="color: black;">MCQ Focus:</strong> Thrombospondin-1 is increased in juvenile dermatomyositis - mediator of angiogenesis
            </div>
        </div>

        <!-- CLASSIFICATION SECTION -->
        <div id="classification" class="section">
            <h2>üè∑Ô∏è Classification System</h2>

            <div class="memory-tip">
                Think of DM classification as a tree: Adult vs Juvenile at the top, then branch into subtypes based on muscle involvement and overlap features.
            </div>

            <div class="feature-grid">
                <div class="feature-card pathognomonic">
                    <h3>üéØ Classical DM</h3>
                    <p>Typical skin findings + muscle weakness</p>
                    <div class="clinical-pearl">
                        Can occur with or without malignancy
                    </div>
                </div>

                <div class="feature-card characteristic">
                    <h3>üé≠ Clinically Amyopathic DM</h3>
                    <p><strong>Confirmed (2 years):</strong> No clinical weakness, normal EMG/MRI/labs for ‚â•2 years</p>
                    <p><strong>Provisional (6 months):</strong> Same criteria but ‚â•6 months</p>
                </div>

                <div class="feature-card compatible">
                    <h3>üî¨ Hypomyopathic DM</h3>
                    <p>No clinical weakness BUT abnormal EMG/MRI/labs</p>
                </div>

                <div class="feature-card rare">
                    <h3>ü§ù Overlap Syndromes</h3>
                    <p>DM + other connective tissue disorders</p>
                </div>
            </div>

            <div class="high-yield">
                <h3>üë∂ Juvenile DM Variants</h3>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4 style="color: black;">&#x1F480; Brunsting Type</h4>
                        <ul style="color: black;">
                            <li>Slow course</li>
                            <li>Calcinosis</li>
                            <li>Progressive weakness</li>
                            <li>Corticosteroid responsive</li>
                            <li>Associated: Anti-CADM-140 (MDA5) with ILD, Anti-p155/140 with extensive skin disease</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4 style="color: black;">&#x26A1; Banker Type</h4>
                        <ul style="color: black;">
                            <li>Rapid onset severe weakness</li>
                            <li>Corticosteroid unresponsive</li>
                            <li>High death rate</li>
                            <li>Severe vasculitis</li>
                            <li>Skin ulcerations, livedo reticularis</li>
                            <li>GI ulceration, pneumatosis &amp; perforation</li>
                            <li>Associated: Anti-NXP-2 (p140)</li>
                        </ul>
                    </div>
                </div>
            </div>
            <div class="other-variants">
                <h3>üåà Other Variants</h3>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>Paraneoplastic</h4>
                    </div>
                    <div class="feature-card">
                        <h4>Wong Type <mark>PRP like </mark> PREVIOUS MCQ</h4>
                    </div>
                    <div class="feature-card">
                        <h4>Drug Induced</h4>
                    </div>
                    <div class="feature-card">
                        <h4>Erythrodermic</h4>
                    </div>
                    <div class="feature-card">
                        <h4>Ichthyisiform</h4>
                    </div>
                    <div class="feature-card">
                        <h4>Pigmented Bronze</h4>
                        <p>Healing of the lesions leaves a bronze color (Addison like)</p>
                    </div>
                    <div class="feature-card">
                        <h4>Psoriasis like</h4>
                    </div>
                    <div class="feature-card">
                        <h4>Bullous</h4>
                    </div>
                    <div class="feature-card">
                        <h4>Ulceration</h4>
                    </div>
                </div>
            </div>


            <div class="clinical-pearl">
                <strong>Gingival telangiectasia:</strong> Specific finding in pediatric DM
            </div>
        </div>
        <!-- CLINICAL FEATURES SECTION -->
        <div id="clinical" class="section">
            <h2 style="color: black;">&#x1F3A8; Clinical Features</h2>

            <div class="quick-facts">
                <h3 style="color: black;">&#x1F551; Timeline of Presentation</h3>
                <div class="fact-item" style="color: black;">muscle weakness initially affects the shoulder and hip girdle musculature</div>
                <div class="fact-item" style="color: black;">Presenting clinically as difficulty raising the arms above the head and arising from a sitting position</div>
                <div class="fact-item" style="color: black;">60% - Skin and muscle weakness appear simultaneously</div>
                <div class="fact-item" style="color: black;">30% - Skin findings appear before muscle weakness</div>
                <div class="fact-item" style="color: black;">10% - Muscle weakness precedes skin lesions</div>
            </div>

            <div class="memory-tip" style="color: black;">
                Cutaneous disease characteristics: Pruritus/burning sensation + Photosensitivity (sunlight/UV)
            </div>

            <div class="high-yield">
                <h3 style="color: black;">&#x1F3A8; Cutaneous Features by Specificity</h3>
                
                <h4 style="color: black;">&#x1F534; PATHOGNOMONIC (Diagnostic)</h4>
                <div class="feature-grid">
                    <div class="feature-card pathognomonic">
                        <h4 style="color: black;">Gottron Papules</h4>
                        <p style="color: black;">Violaceous papules over dorsal-lateral aspect of interphalangeal/MCP joints</p>
                        <div class="clinical-pearl" style="color: black;">
                            Become atrophic with central depression. May have lacy scale + telangiectasia
                        </div>
                    </div>
                    <div class="feature-card pathognomonic">
                        <h4 style="color: black;">Gottron Sign</h4>
                        <p style="color: black;">Confluent macular violaceous erythema ¬± edema over dorsal aspect of interphalangeal/MCP joints, olecranon, patellae, medial malleoli</p>
                    </div>
                    <div class="feature-card pathognomonic">
                        <h4 style="color: black;">Heliotrope Erythema</h4>
                        <p style="color: black;">Periorbital erythema due to orbital oculi (NOT the skin) ¬± periorbital edema</p>
                    </div>
                </div>

                <h4 style="color: black;">&#x1F7E1; CHARACTERISTIC</h4>
                <div class="feature-grid">
                    <div class="feature-card characteristic">
                        <h4 style="color: black;">V Sign</h4>
                        <p style="color: black;">V-shaped erythema on anterior neck/chest</p>
                    </div>
                    <div class="feature-card characteristic">
                        <h4 style="color: black;">Shawl Sign</h4>
                        <p style="color: black;">Erythema over shoulders/upper back</p>
                    </div>
                    <div class="feature-card characteristic">
                        <h4 style="color: black;">Holster Sign</h4>
                        <p style="color: black;">Symmetric erythema on lateral thighs</p>
                    </div>
                    <div class="feature-card characteristic">
                        <h4 style="color: black;">Periungual Changes</h4>
                        <p style="color: black;">Telangiectasias + Samitz sign (dystrophic, ragged cuticles)</p>
                       
                    </div>
                    <div class="feature-card characteristic">
                        <h4 style="color: black;">Scalp Involvement</h4>
                        <p style="color: black;">Scaly, erythematous scalp lesions</p>
                        <div class="mcq-focus" style="color: black;">
                            MCQ: Dilated, tortuous blood vessels are characteristic
                        </div>
                    </div>
                </div>

                <h4 style="color: black;">&#x1F7E2; COMPATIBLE</h4>
                <div class="feature-grid">
                    <div class="feature-card compatible">
                        <h4 style="color: black;">Poikiloderma Atrophicans Vasculare</h4>
                        <p style="color: black;">Poikilodermatomyositis - can be asymmetric</p>
                    </div>
                    <div class="feature-card compatible">
                        <h4 style="color: black;">Facial Changes</h4>
                        <p style="color: black;">Periorbital edema and facial swelling</p>
                    </div>
                </div>

                <h4 style="color: black;">&#x1F7E1; LESS COMMON</h4>
                <div class="feature-grid">
                    <div class="feature-card less-common">
                        <h4 style="color: black;">Vesiculobullous</h4>
                        <p style="color: black;">Vesicles and bullae</p>
                    </div>
                    <div class="feature-card less-common">
                        <h4 style="color: black;">Ulcerative</h4>
                        <p style="color: black;">Skin ulcers with anti MDA5/CADM-140</p>
                    </div>
                    <div class="feature-card less-common">
                        <h4 style="color: black;">Necrotic</h4>
                        <p style="color: black;">Skin necrosis</p>
                    </div>
                    <div class="feature-card less-common">
                        <h4 style="color: black;">Calcinosis cutis</h4>
                        <p style="color: black;">Calcium deposits in the skin</p>
                    </div>
                </div>
                

                <h4 style="color: black;">&#x1F7E3; RARE BUT IMPORTANT</h4>
                <div class="feature-grid">
                    <div class="feature-card rare">
                        <h4 style="color: black;">Mechanic's Hands</h4>
                        <p style="color: black;">Hyperkeratotic, fissured hands</p>
                        <div class="high-yield" style="color: black;">
                            Can indicate worsening interstitial lung disease
                        </div>
                    </div>
                    <div class="feature-card rare">
                        <h4 style="color: black;">Flagellate Erythema</h4>
                        <p style="color: black;">Linear, whip-like erythematous streaks</p>
                        <div class="memory-tip" style="color: black;">
                            Remember flagellate causes: Bleomycin, Still disease, mushrooms, DM, phytophotodermatitis, jellyfish
                        </div>
                    </div>
                    <div class="feature-card rare">
                        <h4 style="color: black;">Wong-type DM</h4>
                        <p style="color: black;">Follicular hyperkeratosis</p>
                    </div>
                    <div class="feature-card rare">
                        <h4 style="color: black;">Deck Chair Sign</h4>
                        <p style="color: black;">Horizontal bands of erythema on lateral thighs</p>
                    </div>
                    <div class="feature-card rare">
                        <h4 style="color: black;">Panniculitis</h4>
                    </div>
                    <div class="feature-card rare">
                        <h4 style="color: black;">Mucinosis</h4>
                    </div>
                    <div class="feature-card rare">
                        <h4 style="color: black;">Erythroderma</h4>
                    </div>
                    <div class="feature-card rare">
                        <h4 style="color: black;">Oral mucosal changes</h4>
                    </div>
                    
                </div>
            </div>
        </div>

        <!-- SYSTEMIC INVOLVEMENT SECTION -->
        <div id="systemic" class="section">
            <h2>ü´Ä Systemic Involvement</h2>

            <div class="high-yield">
                <h3>üí™ Muscle Involvement - Key Facts</h3>
                <div class="fact-item">20% have amyopathic DM (no muscle involvement)</div>
                <div class="fact-item">80% develop muscle involvement in first year</div>
                <div class="fact-item">Slowly progressive, symmetric PROXIMAL weakness</div>
                <div class="fact-item">Extensors > Flexors pattern</div>
                <div class="fact-item">First muscles: Triceps and Quadriceps, then neck muscles</div>
            </div>

            <div class="system-involvement">
                <h3>ü¶¥ Muscle & Joint Features</h3>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>üí™ Muscle Presentation</h4>
                        <ul>
                            <li>Difficulty raising arms above head</li>
                            <li>Trouble arising from sitting</li>
                            <li>Usually painless (pain in late stages)</li>
                            <li>Symmetric proximal weakness</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>‚ö†Ô∏è Muscle Complications</h4>
                        <ul>
                            <li>Muscle atrophy & contractures (Juvenile DM)</li>
                            <li>Diaphragm weakness ‚Üí respiratory failure</li>
                            <li>Cricoarytenoid involvement ‚Üí hoarseness (40%), dysphagia (20-50%)</li>
                            <li>Distal weakness (Anti-NXP, advanced stage)</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>ü¶¥ Joint Involvement (30-40%)</h4>
                        <ul>
                            <li>Arthralgia with morning stiffness</li>
                            <li>Joint pain improves with activity</li>
                            <li>Anti-MDA-5: Non-erosive polyarthropathy</li>
                            <li>Antisynthetase: Erosive AND non-erosive</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div style="color: black;" class="malignancy-alert">
                <h3 style="color: black;">&#x1F9F1; Pulmonary Involvement</h3>
                <div style="color: black;" class="clinical-pearl">
                    <strong style="color: black;">MAJOR PROGNOSTIC FACTOR:</strong> Leading cause of death in DM (when no malignancy present)
                </div>
                <div style="color: black;" class="feature-grid">
                    <div style="color: black;" class="feature-card">
                        <h4 style="color: black;">Anti-MDA5</h4>
                        <p style="color: black;">&#x26A0; Rapidly progressive ILD with POOR PROGNOSIS</p>
                    </div>
                    <div style="color: black;" class="feature-card">
                        <h4 style="color: black;">Antisynthetase (Anti-JO-1)</h4>
                        <p style="color: black;">70% develop ILD</p>
                    </div>
                    <div style="color: black;" class="feature-card">
                        <h4 style="color: black;">Forms of Lung Disease</h4>
                        <ul style="color: black;">
                            <li style="color: black;">Diffuse ILD (most common)</li>
                            <li style="color: black;">Aspiration pneumonia</li>
                            <li style="color: black;">Drug-induced pneumonitis</li>
                            <li style="color: black;">Pulmonary artery hypertension</li>
                        </ul>
                    </div>
                </div>
                <div style="color: black;" class="memory-tip">
                    Usually asymptomatic initially - radiological findings precede symptoms
                </div>
            </div>

            <div class="system-involvement">
                <h3>‚ù§Ô∏è Cardiac Involvement</h3>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>General Features</h4>
                        <ul>
                            <li>Usually asymptomatic</li>
                            <li>Anti-SRP (Signal Recognition Particle)</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>Presentations</h4>
                        <ul>
                            <li>ST segment changes</li>
                            <li>Arrhythmias</li>
                            <li>Left ventricular hypertrophy (LVH)</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="system-involvement">
                <h3>üçΩÔ∏è Gastrointestinal Involvement</h3>
                <div class="high-yield">
                    <strong>‚ö†Ô∏è JDM + Abdominal Pain = ALARMING SIGN for GI involvement</strong>
                </div>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>Presentations</h4>
                        <ul>
                            <li>Vasculopathy affecting bowel wall (Juvenile)</li>
                            <li>Ulceration and perforation</li>
                            <li>Diarrhea, vomiting, constipation</li>
                            <li>Lower esophageal GERD</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>Clinical Significance</h4>
                        <ul>
                            <li>Associated with severe disease</li>
                            <li>Resistant to corticosteroid therapy</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="clinical-pearl">
                <strong>üëÅÔ∏è Ophthalmological:</strong> Retinopathy in Juvenile DM
            </div>
        </div>

        <!-- MALIGNANCY SECTION -->
        <div id="malignancy" class="section">
            <h2>‚ö†Ô∏è Malignancy in Dermatomyositis</h2>

            <div class="malignancy-alert">
                <h3>üéØ Key Malignancy Facts</h3>
                <div class="fact-item">NOT associated with juvenile DM or polymyositis</div>
                <div class="fact-item">Related antibodies: Anti-NXP2, Anti-TIF-1Œ≥</div>
                <div class="fact-item">Most cancers detected within 1-2 years of DM diagnosis</div>
                <div class="fact-item">Risk returns to normal after 5 years (except pancreatic & colorectal)</div>
            </div>

            <div class="feature-grid">
                <div class="feature-card">
                    <h3>üåç Geographic Cancer Patterns</h3>
                    <table class="interactive-table">
                        <thead>
                            <tr>
                                <th>Population</th>
                                <th>Most Common Cancer</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Females</td>
                                <td>Ovarian (most common)</td>
                            </tr>
                            <tr>
                                <td>Males</td>
                                <td>Colorectal (most common)</td>
                            </tr>
                            <tr>
                                <td>Asians</td>
                                <td>Nasopharyngeal</td>
                            </tr>
                            <tr>
                                <td>Overall 2nd most common</td>
                                <td>Lung cancer</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="feature-card">
                    <h3>üîç Other Common Malignancies</h3>
                    <ul>
                        <li>Breast cancer</li>
                        <li>Gastric cancer</li>
                        <li>Pancreatic cancer</li>
                        <li>Lymphomas</li>
                        <li>Other female genital cancers</li>
                    </ul>
                </div>
            </div>

            <div class="mcq-focus">
                <strong>MCQ Focus:</strong> Nasopharyngeal cancer most common in Southern/East Asia
            </div>
            <div style="color: black;" class="prognosis-poor">
                <h3 style="color: black;">&#x1F4C9; Poor Prognostic Factors</h3>
                <div style="color: black;" class="feature-grid">
                    <div style="color: black;" class="feature-card">
                        <h4 style="color: black;">Demographics</h4>
                        <ul style="color: black;">
                            <li style="color: black;">&#x2191; Age (5th-6th decades)</li>
                            <li style="color: black;">Male gender</li>
                        </ul>
                    </div>
                    <div style="color: black;" class="feature-card">
                        <h4 style="color: black;">Clinical Features</h4>
                        <ul style="color: black;">
                            <li style="color: black;">Dysphagia</li>
                            <li style="color: black;">Rapid disease onset</li>
                            <li style="color: black;">Constitutional symptoms</li>
                            <li style="color: black;">Periungual erythema</li>
                            <li style="color: black;">Skin necrosis</li>
                            <li style="color: black;">&#x26A0; Vasculitis in adults (very important)</li>
                        </ul>
                    </div>
                    <div style="color: black;" class="feature-card">
                        <h4 style="color: black;">Laboratory</h4>
                        <ul style="color: black;">
                            <li style="color: black;">Markedly elevated ESR</li>
                            <li style="color: black;">Markedly elevated CK</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="prognosis-good">
                <h3>üìà Protective Factors (Antisynthetase Syndrome)</h3>
                <div class="fact-item">Interstitial lung disease (ILD)</div>
                <div class="fact-item">Raynaud's phenomenon</div>
                <div class="fact-item">Arthritis</div>
            </div>

            <div class="memory-tip">
                Remember: Antisynthetase syndrome patients have LOWER malignancy risk due to protective factors!
            </div>
        </div>

        <!-- DIAGNOSIS & DDX SECTION -->
        <div id="diagnosis" class="section">
            <h2>üî¨ Diagnosis & Approach</h2>

            <div class="sontheimer-criteria">
                <h3>Sontheimer's Proposed Diagnostic Criteria for Cutaneous Dermatomyositis</h3>
                <table class="interactive-table">
                    <thead>
                        <tr>
                            <th>Criteria</th>
                            <th>Features</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Diagnosis Requires</td>
                            <td>
                                Two major criteria, OR<br>
                                One major + Two minor criteria<br>
                                AND<br>
                                Skin biopsy consistent with cutaneous dermatomyositis
                            </td>
                        </tr>
                        <tr>
                            <td>Major Criteria</td>
                            <td>
                                <ul>
                                    <li>Heliotrope sign</li>
                                    <li>Gottron papules</li>
                                    <li>Gottron sign</li>
                                </ul>
                                <p class="mnemonic">"He Got Gottron"</p>
                            </td>
                        </tr>
                        <tr>
                            <td>Minor Criteria</td>
                            <td>
                                <ul>
                                    <li>Macular violaceous erythema (each site = 1 MINOR CRITERION )</li>
                                    <ul>
                                        <li></li><span style="font-size: 0.8em;">Scalp / anterior hairline</span></li>
                                        <li><span style="font-size: 0.8em;">Holster sign (lateral thighs/hips)</span></li>
                                        <li><span style="font-size: 0.8em;">V-neck sign (neck/upper chest)</span></li>
                                        <li><span style="font-size: 0.8em;">Periungual skin</span></li>
                                        <li><span style="font-size: 0.8em;">Linear streaks over dorsal extensor tendons</span></li>
                                        <li><span style="font-size: 0.8em;">Extensor arms/forearms</span></li>
                                        <li><span style="font-size: 0.8em;">Malar, forehead, chin</span></li>
                                        <li><span style="font-size: 0.8em;">Medial malleoli</span></li>
                                        <li><span style="font-size: 0.8em;">Shawl sign (posterior neck/shoulders)</span></li>
                                    </ul>
                                    
                                </ul>
                            </td>
                        </tr>
                        <tr>
                            <td>Additional Minor Features (Supportive)</td>
                            <td>
                                <ul>
                                    <li>Nailfold capillary changes (telangiectasia, hemorrhage, infarcts)</li>
                                    <li>Poikiloderma</li>
                                    <li>Mechanic's hands</li>
                                    <li>Calcinosis cutis</li>
                                    <li>Ulcers (cutaneous)</li>
                                    <li>Pruritus</li>
                                </ul>
                                
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>


            <div class="treatment-box">
                <h3>üß™ Laboratory Approach</h3>
                
                <h4>General Labs</h4>
                <p>CBC/Diff, ESR/CRP, UE, LFT, TSH (can cause weakness)</p>
                <p><strong>Children:</strong> Add fasting glucose & triglycerides("lipodystrophy and metabolic abnormalities, including hypertriglyceridemia and insulin resistance, have become increasingly recognized as potential complications of juvenile dermatomyositis)</p>
                <p>Antibodies</p>

                <h4>üéØ Muscle Investigations</h4>
                <table class="interactive-table">
                    <thead>
                        <tr>
                            <th>Test</th>
                            <th>Significance</th>
                            <th>Notes</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>CK-MM</td>
                            <td>Most specific & sensitive</td>
                            <td>Normal level = poor prognosis ( SPECIACLLY in patients with anti-MDA5 (CADM) antibodies have a high risk of rapidly progressive lung disease and a poor prognosis despite a lack of muscle disease)</td>
                        </tr>
                        <tr>
                            <td>Aldolase</td>
                            <td>Less specific</td>
                            <td>Useful when CK normal</td>
                        </tr>
                        <tr>
                            <td>EMG</td>
                            <td>Sensitive, not specific</td>
                            <td>Shows myopathic changes</td>
                        </tr>
                        <tr>
                            <td>Myoglobin</td>
                            <td>Additional marker</td>
                            <td>Along with urine creatinine</td>
                        </tr>
                    </tbody>
                </table>

                <div class="clinical-pearl">
                    <strong>GGT:</strong> If elevated ‚Üí hepatic source (not muscle)
                    <strong>AST/ALT:</strong> Elevated liver transaminases (AST, ALT) do not necessarily indicate liver disease but are often elevated due to muscle damage 
                </div>
            </div>

            <div class="system-involvement">
                <h3>üñºÔ∏è Imaging & Biopsy</h3>
                
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>MRI Benefits</h4>
                        <ul>
                            <li>Differentiate DM vs steroid myopathy</li>
                            <li>Direct biopsy site selection</li>
                            <li>Monitor treatment response</li>
                            <li>Muscle edema correlates with CK levels</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>ü•á Muscle Biopsy (Gold Standard)</h4>
                        <ul>
                            <li><strong>Site:</strong> Triceps > deltoid (often spared early)</li>
                            <li><strong>Alternative:</strong> Most tender area or highest MRI uptake</li>
                            <li><strong>Avoid:</strong> EMG needle sites</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="high-yield">
                <h3 style="color: black;">üè• Organ-Based Screening</h3>
                <table class="interactive-table">
                    <thead>
                        <tr>
                            <th style="color: black;">System</th>
                            <th style="color: black;">Initial Test</th>
                            <th style="color: black;">If Abnormal</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td style="color: black;">ü´Å Lung</td>
                            <td style="color: black;">PFT</td>
                            <td style="color: black;">HRCT chest</td>
                        </tr>
                        <tr>
                            <td style="color: black;">‚ù§Ô∏è Cardiac</td>
                            <td style="color: black;">ECG</td>
                            <td style="color: black;">Echo + Holter monitoring</td>
                        </tr>
                        <tr>
                            <td style="color: black;">üçΩÔ∏è GI</td>
                            <td style="color: black;">Clinical assessment</td>
                            <td style="color: black;">Barium swallow</td>
                        </tr>
                        <tr>
                            <td style="color: black;">ü¶¥ Bone</td>
                            <td style="color: black;">N/A</td>
                            <td style="color: black;">DEXA if planning steroids</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="malignancy-alert">
                <h3 style="color: black;">üîç Malignancy Screening Protocol</h3>
                
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4 style="color: black;">üë®‚Äç‚öïÔ∏è Adults</h4>
                        <p style="color: black;"><strong>Timing:</strong> At diagnosis + annually for 3 years + follow-up every 4-6 months</p>
                    </div>
                    <div class="feature-card">
                        <h4 style="color: black;">üë∂ Pediatrics</h4>
                        <p style="color: black;"><strong>Screening:</strong> NOT needed</p>
                    </div>
                </div>

                <h4>üß™ Laboratory Screening</h4>
                <ul>
                    <li>UA and FOBT</li>
                    <li><strong>Men:</strong> PSA (prostate)</li>
                    <li><strong>Women:</strong> CA-125 (ovarian)</li>
                    <li><strong>Both:</strong> CA 19-9 (pancreatic/biliary)</li>
                </ul>

                <h4>üìã Diagnostic Imaging</h4>
                <ul>
                    <li><strong>All:</strong> Pan-CT (chest, abdomen, pelvis)</li>
                    <li><strong>Colonoscopy if:</strong> Age appropriate, iron deficiency anemia, positive occult blood, symptomatic</li>
                    <li><strong>Endoscopy:</strong> If colonoscopy negative but concerning features</li>
                    <li><strong>Women:</strong> Mammogram, Pap smear, transvaginal pelvic ultrasound</li>
                </ul>
            </div>

            <div class="system-involvement">
                <h3>üî¨ Histopathology</h3>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>Similar to SLE</h4>
                        <ol>
                            <li>Epidermal atrophy</li>
                            <li>Basement membrane degeneration</li>
                            <li>Vacuolar alteration of basal keratinocytes</li>
                            <li>Dermal changes: dilated vessels + sparse lymphocytic infiltrate</li>
                            <li>Interstitial mucin depositions</li>
                        </ol>
                    </div>
                    <div class="feature-card">
                        <h4>Differences from SLE</h4>
                        <ul>
                            <li>Less lymphocyte infiltration</li>
                            <li>Less eccrine involvement</li>
                            <li>Rare lymphoid follicles</li>
                        </ul>
                    </div>
                </div>
                <div class="clinical-pearl">
                    <strong>Gottron papules:</strong> Interface dermatitis BUT with acanthosis + hyperkeratosis (not atrophy)
                </div>
            </div>

            <div class="treatment-box">
                <h3>üìä CDASI Score</h3>
                <p>Cutaneous Dermatomyositis Area and Severity Index measures:</p>
                <ul>
                    <li><strong>Activity:</strong> Erythema, scale, excoriation, ulceration</li>
                    <li><strong>Damage:</strong> Poikiloderma, calcinosis</li>
                    <li><strong>Locations:</strong> 15 anatomic sites</li>
                    <li><strong>Specific measures:</strong> Gottron's papules, periungual changes, alopecia</li>
                </ul>
            </div>
        </div>

        <!-- TREATMENT & PROGNOSIS SECTION -->
        <div id="treatment" class="section">
            <h2 style="color: black;">üíä Treatment & Prognosis</h2>

            <div class="clinical-pearl" style="color: black;">
                <strong>Key Treatment Principle:</strong> Skin response is less adequate than muscle (especially scalp pruritus) - may persist for years after muscle remission
            </div>

            <div class="treatment-box" style="color: black;">
                <h3>üõ°Ô∏è General Measures</h3>
                <div class="fact-item">Photoprotection (sunscreen, protective clothing)</div>
                <div class="fact-item">Stop smoking</div>
                <div class="fact-item">Vitamin D supplements</div>
            </div>

            <div class="high-yield" style="color: black;">
                <h3>üé® Cutaneous Treatment</h3>
                
                <h4>Topical Therapy</h4>
                <ul>
                    <li><strong>Topical steroids:</strong> Class I-II potency</li>
                    <li><strong>Topical tacrolimus:</strong> Alternative to steroids</li>
                </ul>

                <h4>üíä Oral Medications</h4>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>Hydroxychloroquine (HCQ)</h4>
                        <p><strong>Indication:</strong> Limited skin involvement (adjuvant only)</p>
                        <p><strong>Dosing:</strong></p>
                        <ul>
                            <li>Adults: 200mg BID</li>
                            <li>Pediatric: 3-5mg/kg divided in 2 doses</li>
                        </ul>
                        <p><strong>Alternatives:</strong> Combine with quinacrine or switch to chloroquine</p>
                        <div class="clinical-pearl" style="color: black;">
                            If no improvement within 3 months ‚Üí Treatment failure
                        </div>
                    </div>
                </div>

                <h4>üîÑ Systemic Immunosuppression</h4>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>Methotrexate (MTX)</h4>
                        <p><strong>Use:</strong> Systemic or extensive skin involvement</p>
                        <p><strong>Avoid if:</strong> ILD present</p>
                        <p><strong>Alternative:</strong> Switch to MMF if not improving</p>
                    </div>
                    <div class="feature-card">
                        <h4>Mycophenolate Mofetil (MMF)</h4>
                        <p><strong>Use:</strong> If ILD present (give with steroids)</p>
                        <p><strong>Alternative:</strong> If MTX fails</p>
                    </div>
                    <div class="feature-card">
                        <h4>Rituximab</h4>
                        <p><strong>Indications:</strong></p>
                        <ul>
                            <li>Vasculopathy with skin ulceration</li>
                            <li>Positive anti-MDA5</li>
                            <li>Children with anti-NXP2</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>IVIG (FDA Approved)</h4>
                        <p><strong>Designation:</strong> Single most effective agent</p>
                        <p><strong>Use:</strong> First-line in life-threatening situations including dysphagia</p>
                    </div>
                    <div class="feature-card">
                        <h4>Cyclosporine</h4>
                        <p><strong>Use:</strong> Lung involvement</p>
                        <p><strong>Add:</strong> Cyclophosphamide if not improved</p>
                    </div>
                </div>

                <div class="clinical-pearl" style="color: black;">
                    <strong>PDL (Pulsed Dye Laser):</strong> For poikiloderma treatment
                </div>
            </div>

            <div class="malignancy-alert" style="color: black;">
                <h3>üí™ Muscle Disease Treatment</h3>
                
                <h4>ü•á First-Line: Systemic Corticosteroids</h4>
                <ul>
                    <li><strong>Dose:</strong> 1mg/kg/day</li>
                    <li><strong>Taper:</strong> 50% after 6 months, remaining 50% over 1.5 years</li>
                    <li><strong>Total duration:</strong> 2-3 years</li>
                </ul>

                <div class="high-yield" style="color: black;">
                    <h4>‚ö° High-Dose Scenarios</h4>
                    <p><strong>If progressive disease OR CK >1000:</strong></p>
                    <ul>
                        <li>Pulse methylprednisolone 1000mg/day √ó 3 days</li>
                        <li>OR increase dose to 1.5mg/kg</li>
                        <li>OR add other immunosuppressive</li>
                    </ul>
                </div>

                <h4>üîÑ Second-Line Options</h4>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>Methotrexate</h4>
                        <p><strong>Avoid if:</strong> Lung disease or positive anti-JO-1</p>
                    </div>
                    <div class="feature-card">
                        <h4>Azathioprine</h4>
                        <p><strong>Dose:</strong> 2-3mg/kg/day</p>
                    </div>
                    <div class="feature-card">
                        <h4>Others</h4>
                        <ul>
                            <li>Cyclosporine (also for lung disease)</li>
                            <li>IVIG</li>
                            <li>MMF</li>
                            <li>Rituximab</li>
                            <li>Sirolimus</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="prognosis-good" style="color: black;">
                <h3>üìà Good Prognosis Factors</h3>
                <div class="fact-item">Early systemic treatment</div>
                <div class="fact-item">Juvenile onset</div>
                <div class="fact-item">Overlap syndromes</div>
            </div>

            <div class="prognosis-poor" style="color: black;">
                <h3>üìâ Poor Prognosis Factors</h3>
                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>Demographics</h4>
                        <ul>
                            <li>Older age</li>
                            <li>No Raynaud's phenomenon</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>Disease Features</h4>
                        <ul>
                            <li>Progressive disease</li>
                            <li>Extensive cutaneous involvement of trunk</li>
                            <li>Late treatment (>24 months of muscle weakness)</li>
                            <li>Longer duration before diagnosis</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>Systemic Involvement</h4>
                        <ul>
                            <li>Pulmonary disease</li>
                            <li>Cardiac disease</li>
                            <li>Dysphagia</li>
                            <li>Malignancy</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>Cutaneous Features</h4>
                        <ul>
                            <li>Bullous lesions</li>
                            <li>Ulceration</li>
                        </ul>
                    </div>
                    <div class="feature-card">
                        <h4>Laboratory</h4>
                        <ul>
                            <li>WBC >10,000</li>
                            <li>Normal CK (paradoxically poor)</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="malignancy-alert" style="color: black;">
                <h3>ü¶¥ Calcinosis Cutis - Special Focus</h3>
                
                <div class="quick-facts">
                    <h4>üìä Epidemiology</h4>
                    <div class="fact-item">Juvenile DM: 25-70%</div>
                    <div class="fact-item">Adult DM: <20%</div>
                    <div class="fact-item">Associated antibodies: Anti-p140 (NXP-2), Anti-MDA5</div>
                </div>

                <div class="feature-grid">
                    <div class="feature-card">
                        <h4>üìç Types in Children</h4>
                        <ol>
                            <li>Superficial</li>
                            <li>Deep</li>
                            <li>Myofascial</li>
                            <li>Mixed</li>
                            <li>Periarticular</li>
                            <li>Universalis</li>
                        </ol>
                    </div>
                    <div class="feature-card">
                        <h4>‚ö†Ô∏è Risk Factors (JDM)</h4>
                        <ul>
                            <li>Longer disease duration </li>
                            <li>Younger age of diagnosis </li>
                            <li>Sustained disease activity </li>
                            <li>Internal involvement </li>
                        </ul>

                        <ul>
                            </ul>
                        </div>
                    </div>
                </div>
                <div class="feature-card">
                    <h4> Treatment of Calcinosis Cutis</h4>
                    <ul>
                        <li><strong>A:</strong> Avoid calcium and phosphate, Aluminum hydroxide, Antibiotic: Minocycline</li>
                        <li><strong>B:</strong> Probencid / bisphosphonates (No effect)</li>
                        <li><strong>C:</strong> Colchicine / CO<sub>2</sub> laser</li>
                        <li><strong>S:</strong> Sodium thiosulfate (Topical or intralesional), 12.5mg/ml, Surgical excision if painful or interferes with function</li>
                        <li><strong>D:</strong> Diltiazem for long term management (calcium transport into cells) / Debridement</li>
                        <li><strong>E:</strong> ECSW</li>
                        <li><strong>I:</strong> IVIG, Iontophoresis of acetic acid, ultrasound</li>
                    </ul>
                </div>
    
                <div class="memory-tip">
                    <strong>Calcinosis Treatment Mnemonic:</strong> "A Busy Clinician Should Definitely Examine Injuries" = A-B-C-S-D-E-I approach
                </div>
            </div>
            <!-- ORAL EXAM QUESTIONS SECTION -->
<div id="oral-exam" class="section">
    <h2>üé§ Oral Exam Questions</h2>
    
    <div class="high-yield">
        <h3>üìö Interactive Q&A for Saudi Board Oral Examination</h3>
        <p>Click on any question card to reveal the complete answer. Master these for your oral exam success!</p>
    </div>

    <!-- PATHOGENESIS & TRIGGERS -->
    <div class="system-involvement">
        <h3>üß¨ Pathogenesis & Triggers</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What is the pathogenesis of dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        <strong>Unknown exact mechanism</strong><br>
                        ‚Ä¢ Genetic predisposition + environmental factors + autoimmune mechanisms<br>
                        ‚Ä¢ Both antibody-dependent and involves classical complement cascade activation<br>
                        ‚Ä¢ Leads to capillary destruction ‚Üí ischemia and microinfarction
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>Mention all triggers of dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        <strong>Infections:</strong> Picornavirus, E.coli, Echovirus, Coxsackievirus-9<br>
                        <strong>Environmental:</strong> Malignancy, Smoking, UV exposure, Tattoo, IsaLean herbal injection<br>
                        <strong>Medications:</strong> Hydroxyurea, statins, TNF-Œ± inhibitors, NSAIDs, cyclophosphamides, ipilimumab, BCG vaccine, omeprazole, terbinafine, IFN-alpha2b, D-penicillamine
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- ASSOCIATIONS & CLASSIFICATIONS -->
    <div class="treatment-box">
        <h3>üîó Disease Associations & Classifications</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the autoimmune diseases associated with dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        ‚Ä¢ Hashimoto's disease<br>
                        ‚Ä¢ Graves disease<br>
                        ‚Ä¢ Vitiligo<br>
                        ‚Ä¢ Dermatitis herpetiformis<br>
                        ‚Ä¢ Primary biliary cirrhosis<br>
                        ‚Ä¢ Type I DM
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the malignancy-associated autoantibodies in dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 16px; text-align: left;">
                        ‚Ä¢ Anti-TIF-1gamma antibodies<br>
                        ‚Ä¢ Anti-NXP2 antibodies
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the classifications of dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        <strong>Adult dermatomyositis:</strong><br>
                        - Classic<br>
                        - Classic with malignancy<br>
                        - Classic as part of overlapping connective tissue disorder<br>
                        - Amyopathic<br>
                        - Hypomyopathic<br><br>
                        <strong>Juvenile dermatomyositis:</strong><br>
                        - Classic<br>
                        - Amyopathic<br>
                        - Hypomyopathic
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- DEFINITIONS -->
    <div class="clinical-pearl">
        <h3>üìñ Key Definitions</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What is the definition of provisional amyopathic or hypomyopathic DM?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        Dermatomyositis cutaneous lesions without muscle weakness and the muscle enzymes are normal for <strong>‚â•6 months</strong>
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What is the definition of confirmed amyopathic or hypomyopathic DM?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        Dermatomyositis cutaneous lesions without muscle weakness and the muscle enzymes are normal for <strong>‚â•24 months</strong>
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What is the percentage of malignancy in adult dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 16px; text-align: center;">
                        <strong>25% (1/4th of adult patients)</strong>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- ANTISYNTHETASE SYNDROME -->
    <div class="mcq-focus">
        <h3>üéØ Antisynthetase Syndrome</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What is the manifestation of antisynthetase syndrome?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        ‚Ä¢ Myositis<br>
                        ‚Ä¢ Mechanics hands<br>
                        ‚Ä¢ Erosive polyarthritis<br>
                        ‚Ä¢ Fever<br>
                        ‚Ä¢ Raynaud phenomenon<br>
                        ‚Ä¢ Interstitial lung disease
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- CLINICAL FEATURES -->
    <div class="high-yield">
        <h3>üé® Clinical Features</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the pathognomonic features of dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 16px; text-align: left;">
                        ‚Ä¢ Gottron's papules<br>
                        ‚Ä¢ Gottron's sign<br>
                        ‚Ä¢ Heliotrope rash
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the characteristic signs of dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        ‚Ä¢ Periungual erythema and telangiectasia<br>
                        ‚Ä¢ Shawl sign<br>
                        ‚Ä¢ V sign<br>
                        ‚Ä¢ Holster sign<br>
                        ‚Ä¢ Atrophic, scaly, and erythematous scalp lesions
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the distinguishing clinical features of dermatomyositis from SLE?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        ‚Ä¢ Poikiloderma in DM is <strong>pink to violet</strong> vs SLE is <strong>red</strong><br>
                        ‚Ä¢ Skin lesions of DM are <strong>tensely pruritic</strong><br>
                        ‚Ä¢ <strong>Knuckles are involved</strong> in DM but NOT in SLE
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- AUTOANTIBODIES -->
    <div class="system-involvement">
        <h3>üß™ Autoantibodies & Phenotypes</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>Mention all autoantibodies of dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        ‚Ä¢ Anti-synthetase antibodies (anti-Jo1, anti-PL7)<br>
                        ‚Ä¢ Anti-SRP antibody<br>
                        ‚Ä¢ Anti-MI-2 antibody<br>
                        ‚Ä¢ Anti-TIF-1gamma (p155) antibody<br>
                        ‚Ä¢ Anti-NXP2 (p140) antibody<br>
                        ‚Ä¢ Anti-SAE antibody<br>
                        ‚Ä¢ Anti-MDA5 antibody (CADM-140)
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the phenotypic features of anti-Mi2 antibody +ve dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        ‚Ä¢ Classic cutaneous disease (shawl sign, poikiloderma, flagellate erythema)<br>
                        ‚Ä¢ <strong>Good prognosis</strong>
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the phenotypic features of anti-SRP antibody +ve dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        ‚Ä¢ Acute onset necrotizing muscle disease<br>
                        ‚Ä¢ <strong>Refractory to treatment</strong>
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the phenotypic features of anti-TIF-1gamma (p155) antibody +ve dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        ‚Ä¢ <strong>Malignancy association</strong> in adult dermatomyositis<br>
                        ‚Ä¢ Palmar hyperkeratotic papules<br>
                        ‚Ä¢ Psoriasiform lesions<br>
                        ‚Ä¢ Ovoid palatal patch<br>
                        ‚Ä¢ Red-on-white telangiectatic patch
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the phenotypic features of anti-NXP2(p140) antibody +ve dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        ‚Ä¢ <strong>Malignancy association</strong> in adult dermatomyositis<br>
                        ‚Ä¢ Calcinosis cutis<br>
                        ‚Ä¢ Peripheral edema<br>
                        ‚Ä¢ Dysphagia<br>
                        ‚Ä¢ Myalgia<br>
                        ‚Ä¢ Mild skin disease
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the phenotypic features of anti-MDA5 antibody +ve dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        ‚Ä¢ Cutaneous ulceration<br>
                        ‚Ä¢ Oral ulceration<br>
                        ‚Ä¢ Alopecia<br>
                        ‚Ä¢ Interstitial lung disease<br>
                        ‚Ä¢ Painful palmar papules (inverse gottron papules)<br>
                        ‚Ä¢ Panniculitis
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the phenotypic features of anti-SAE antibody +ve dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        ‚Ä¢ Fever and weight loss<br>
                        ‚Ä¢ It is <strong>predictive of hydroxychloroquine drug eruption</strong>
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What is the prevalence of positive ANA in dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 18px; text-align: center;">
                        <strong>40%</strong>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- PROGNOSIS -->
    <div class="malignancy-alert">
        <h3>üìä Prognosis & Risk Factors</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What is the major prognostic factor for death after malignancy in dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 16px; text-align: center;">
                        <strong>Cardiac disease (arrhythmias)</strong>
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>Mention all poor prognostic factors in dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        ‚Ä¢ Malignancy<br>
                        ‚Ä¢ Older age<br>
                        ‚Ä¢ Progressive disease<br>
                        ‚Ä¢ Initiation of treatment after two years of muscle weakness<br>
                        ‚Ä¢ Longer duration of symptoms before the diagnosis<br>
                        ‚Ä¢ Pulmonary disease<br>
                        ‚Ä¢ Dysphagia<br>
                        ‚Ä¢ Extensive skin involvement of the trunk
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- MALIGNANCY -->
    <div class="prognosis-poor">
        <h3>‚ö†Ô∏è Malignancy</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the common malignancies associated with dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        ‚Ä¢ <strong>Genitourinary malignancy</strong> (especially ovarian cancer)<br>
                        ‚Ä¢ Colon cancer<br>
                        ‚Ä¢ <strong>Nasopharyngeal carcinoma</strong> in Southwest Asian<br>
                        ‚Ä¢ Breast, lung, gastric, pancreatic cancers, and lymphoma
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>When does the risk of malignancy return to baseline in dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 18px; text-align: center;">
                        <strong>After five years</strong>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- HISTOPATHOLOGY & DIAGNOSIS -->
    <div class="treatment-box">
        <h3>üî¨ Histopathology & Diagnosis</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the histopathological features of dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 14px; text-align: left;">
                        ‚Ä¢ Epidermal atrophy<br>
                        ‚Ä¢ Vacuolar interface dermatitis<br>
                        ‚Ä¢ Dermal mucin deposition<br>
                        ‚Ä¢ Sparse lymphocytic infiltrates
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the preferred lesions for biopsy in dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 16px; text-align: center;">
                        <strong>Old lesions (3-6 months)</strong>
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>How can we differentiate between myositis of dermatomyositis and steroid-induced myopathy?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 11px; text-align: left;">
                        ‚Ä¢ The onset of weakness is a <strong>month or more after starting steroid therapy</strong><br>
                        ‚Ä¢ Presence of <strong>cushingoid features</strong> in steroid-induced myopathy<br>
                        ‚Ä¢ <strong>Normal serum muscle enzyme levels</strong> in steroid-induced myopathy<br>
                        ‚Ä¢ Reduce the dose of steroid and see if there is improvement in weakness (usually, improve 3-4 weeks after dose reduction)<br>
                        ‚Ä¢ EMG<br>
                        ‚Ä¢ Muscle biopsy
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- SYSTEMIC MANIFESTATIONS -->
    <div class="system-involvement">
        <h3>ü´Ä Systemic Manifestations</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What are the systemic manifestations of dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        ‚Ä¢ Interstitial lung disease<br>
                        ‚Ä¢ Cardiovascular risk factors are increased<br>
                        ‚Ä¢ Diastolic dysfunction<br>
                        ‚Ä¢ Myocarditis, arrhythmias<br>
                        ‚Ä¢ Dysphagia<br>
                        ‚Ä¢ GI infarction or perforation<br>
                        ‚Ä¢ <strong>Lipodystrophy (in pediatrics)</strong><br>
                        ‚Ä¢ <strong>Growth failure (in pediatrics)</strong>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- TREATMENT -->
    <div class="prognosis-good">
        <h3>üíä Treatment Pearls</h3>
        
        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What is the only medication found to be associated with the improvement of nail fold capillary abnormalities?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 18px; text-align: center;">
                        <strong>Rituximab</strong>
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>What is the only systemic medication that has robust data supporting its use for vasculopathy lesions (ulcerations, nail fold capillary abnormalities, inverse gottron papules)?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 18px; text-align: center;">
                        <strong>Rituximab</strong>
                    </div>
                </div>
            </div>
        </div>

        <div class="flip-card">
            <div class="flip-card-inner">
                <div class="flip-card-front">
                    <h4>Mention emerging therapies of use in dermatomyositis?</h4>
                </div>
                <div class="flip-card-back">
                    <div style="font-size: 12px; text-align: left;">
                        ‚Ä¢ <strong>Tocilizumab</strong> (IL6 inhibitor)<br>
                        ‚Ä¢ <strong>Alemtuzumab</strong> (anti-CD52)<br>
                        ‚Ä¢ <strong>Abatacept</strong> (co-stimulatory modulator)<br>
                        ‚Ä¢ <strong>Infliximab</strong> (TNF alpha inhibitor)<br>
                        ‚Ä¢ <strong>Anakinra</strong> (IL-1 inhibitor)<br>
                        ‚Ä¢ <strong>Eculizumab</strong> (CS blocking agent)<br>
                        ‚Ä¢ <strong>Apremilast</strong> (PDE4 inhibitor)
                    </div>
                </div>
            </div>
        </div>
    </div>
</div>
        </div>

        <script>
        function showSection(sectionId) {
            // Hide all sections
            const sections = document.querySelectorAll('.section');
            sections.forEach(section => {
                section.classList.remove('active');
            });
            
            // Remove active class from all tabs
            const tabs = document.querySelectorAll('.nav-tab');
            tabs.forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Show selected section
            document.getElementById(sectionId).classList.add('active');
            
            // Add active class to clicked tab
            event.target.classList.add('active');
        }
        </script>
    </div>
</body>
</html>
